Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce news that the company's Investigational New Animal Drug (INAD), featuring a dissolvable doxorubicin-containing microneedle array, has been granted Minor Use in Major Species Designation or MUMS by the U.S. Food and Drug Administration. This designation marks a significant step forward for Medicus Pharma’s mission to revolutionize veterinary oncology.

The FDA's MUMS designation is a pivotal milestone, akin to the Orphan Drug status for human medicines. It offers Medicus Pharma an extended 7-year period of exclusive marketing rights following approval or conditional approval, provided the company fulfills all regulatory requirements for maintaining the designation. This exclusivity positions the company to make a profound impact on treating external squamous cell carcinoma (SCC) in horses.

The innovative doxorubicin-containing microneedle array is a patent-protected, dissolvable transdermal patch designed with cellulose-based microneedles. These microneedles are tip-loaded with doxorubicin, a potent chemotherapy agent. When applied, the microneedles penetrate the stratum corneum layer of the skin, creating temporary microchannels. This allows the microneedles to reach the tumor, dissolve, and release doxorubicin directly into the targeted area, effectively eradicating cancer cells while minimizing systemic side effects.

Squamous cell carcinoma is a significant concern in horses, particularly in adult or aged animals with white or partially white coats. Breeds such as Appaloosa, Belgian, American Paint, and Pinto are especially susceptible. SCC typically develops in areas with minimal pigmentation and sparse hair, often around mucous membranes. Commonly affected areas include the eyes, lips, nose, anus, and external genitalia. With an overall incidence rate of 2-3%, this condition impacts a notable portion of the U.S. horse population, estimated to be between 6.6 and 7.25 million horses.

#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CancerTreatment #HorseHealth #FDAApproval #InnovationInMedicine #SquamousCellCarcinoma #EquineCare #RazaBokhari #MUMSDesignation #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ideal Power CEO Daniel Brdar joined Steve Darling from Proactive to share news announcing the company’s first design win for its innovative solid-state circuit breakers with a leading Asian circuit protection equipment manufacturer serving the industrial and utility markets.

This milestone was solidified through a joint development agreement between Ideal Power and its new partner. The collaboration involves designing, prototyping, and testing an SSCB product utilizing Ideal Power’s patented B-TRAN technology. Development is on track for completion in Q2 2025, with commercial sales expected to follow later in the year.

Brdar highlighted the revenue potential stemming from this partnership, estimating that the customer’s first B-TRAN-enabled product could generate several hundred thousand dollars in the first year alone. As adoption scales, the opportunity could surpass $1 million in revenue during the second year of sales.

The partner company has a robust, decades-long reputation for innovation and a significant foothold in the Asian market. Currently selling over 200,000 circuit breakers annually, they cater to large, established customers in sectors such as renewable energy, industrial equipment circuit protection, utility grid infrastructure, and power distribution.

The initial SSCB product will specifically target grid-tied solar and energy storage providers, as well as utility electric distribution networks, positioning Ideal Power’s B-TRAN technology as a transformative solution for modern energy systems. B-TRAN solid-state circuit breakers offer significant advantages, including higher efficiency, lower power losses, and greater reliability compared to traditional mechanical circuit breakers.

Brdar emphasized that this design win represents a pivotal step for Ideal Power, marking the first commercial application of B-TRAN in the circuit protection market.

#proactiveinvestors #idealpowerinc #nasdaq #ipwr

#BTranTechnology #SolidStateCircuitBreakers #EnergyInnovation #IndustrialTech #RenewableEnergy #ProactiveInvestors #ElectricVehicles #TechPartnerships #CleanEnergy

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Brent Charleton, President and CEO of Enwave Corporation joined Steve Darling from Proactive to announce a new partnership with ELEA Technology, a global leader in pulsed electric field technology. This agreement allows ELEA to use EnWave’s Radiant Energy Vacuum technology in combination with PEF pre-treatment to create healthier potato and vegetable snacks. The goal is to reduce or eliminate frying while maintaining superior taste, texture, and nutrition. As part of the agreement, ELEA will lease a 10kW REV™ machine at its German facility starting in February 2025 for a minimum three-month term.

Charleton emphasized that combining PEF and REV™ technologies offers significant potential to redefine snack production by delivering high-quality products with fewer unhealthy processes.

In addition to this partnership, EnWave shared strong consolidated financial results for the fourth quarter and fiscal year ending September 30, 2024. The company reported a 149% increase in Q4 revenue compared to the same period in 2023. This growth was driven by the resale of a large-scale machine and higher royalties. EnWave also achieved a 243% increase in gross margins, reflecting improved operational efficiency and growing demand for its technology.

EnWave also announced the appointment of Louise Lalonde to its Board of Directors as the new Audit Committee Chair. Lalonde, a Certified Public Accountant with over 30 years of experience in accounting, governance, and compliance, brings expertise from her tenure at Price Waterhouse Coopers and leadership roles in manufacturing and service sectors. Her appointment follows the retirement of current Audit Committee Chair Mary Ritchie, who was recognized for her valuable contributions to the company.

#proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #MilitaryContracts #FoodIndustryInnovation #ShelfStableRations #GlobalExpansion #USArmy

#HealthierSnacks #ELEATechnology #FoodInnovation #REVTechnology #FinancialGrowth #HealthyEating #CEOInterview #InvestingInTech #SnackRevolution

#investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

PreveCeutical Medical Chairman Stephen Van Deventer joined Steve Darling from Proactive to share updates on the company’s strategic advances in gene therapy and its wholly-owned subsidiary, BioGene Therapeutics. BioGene focuses on addressing diabetes and obesity through innovative therapies targeting the PTP1B gene in the brain, which is also linked to colon and breast cancers.

Van Deventer emphasized the global need for new treatments in diabetes and obesity as key reasons for selecting these areas as initial targets. He stated, “Once we manage to get the proof of concept done and get it to commercialization, it's a very viable business plan.” The advancements aim to provide solutions for widespread health challenges while establishing a robust business opportunity.

The conversation also underscored the strength of BioGene’s team, which boasts deep scientific and corporate expertise, positioning the subsidiary to drive success in its mission.

Looking ahead, PreveCeutical plans to further its other programs by 2025. These include its Sol-Gel drug delivery platform, designed for efficient medication delivery, and its non-addictive analgesic program, which addresses pain management without the risk of addiction.

#proactiveinvestors #preveceutical #biogenetherapeutics #cse #prev #otcqb #prvcf

BioGeneTherapeutics #GeneTherapy #DiabetesTreatment #ObesitySolutions #BiotechInnovation #PTP1B #MedicalResearch #HealthcareInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to share positive results from metallurgical studies conducted at the company’s Fran Gold Project in British Columbia. The studies demonstrated an impressive total gold recovery of 97%, achieved through a combination of 67% recovery by gravity separation and 30% by flotation.

The head grade, originally reported at 0.9 ounces per ton gold, was significantly upgraded during testing. Gravity concentration yielded 8.54 opt gold, followed by flotation results of 2.69 opt gold, producing a final combined concentrate of 11.23 opt gold—representing an extraordinary 12x concentration of the material.

Lazerson elaborated on the advanced methodologies employed, explaining that samples were digested using a three-acid microwave digestion system. This system applies precise microwave energy to heat the acid mixture evenly and rapidly, ensuring complete dissolution of the sample matrix. Following digestion, the emissions were analyzed using an optical emission spectrometer, enabling precise quantification of elements such as barium, calcium, cadmium, cobalt, chromium, copper, iron, potassium, lithium, magnesium, manganese, sodium, nickel, lead, strontium, and zinc.

The metallurgical grind study was conducted on 1,000-gram samples to determine the time required to achieve a target grind size of 90% passing 106 microns (um). Two portions of the material were milled accordingly and subjected to gravity separation and flotation testing, resulting in the exceptional recovery and concentration outcomes.

In addition to these metallurgical advancements, Lazerson provided updates on the loading and transportation of a 120-ton shipment of gold-bearing material to the company’s Bishop Gold Mill in California. The shipment, totaling 240,000 pounds, consisted of 82 super-sacks with an average weight of 2,900 pounds each. Lazerson highlighted that fewer sacks were required than anticipated, suggesting higher metal content, as gold at the Fran Project is often associated with up to 20% iron content. The first rail shipment has now been completed, with the initial load expected to arrive at its destination imminently.

#proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources

#MetallurgicalStudies #NorthBayResources #MiningInnovation #FranGoldProject #GoldRecovery #ResourceDevelopment #InvestingInGold #MiningUpdates #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Oriole Resources PLC (AIM:ORR) CEO Martin Rosser talked with Proactive's Stephen about the company's progress at the Mbe gold project in Cameroon. Rosser shared an update on the maiden drilling campaign, which includes 24 holes over a 6,590-meter program. The initial results are promising, with the first hole extending 358 meters and showing geological similarities to earlier trenching studies.

Rosser emphasised the importance of the drilling program in identifying potential gold resources at depth, following significant surface results from soil sampling and trenching at the Mbe South prospect. The first assay results are anticipated early in the new year, and the program continues steadily with the second hole already underway.

Rosser concluded by expressing optimism about the campaign's outcomes and the upcoming analysis from the laboratory in Ghana.

Visit Proactive's YouTube channel for more updates, and don’t forget to like, subscribe, and enable notifications to stay informed about the latest developments.

#OrioleResources #GoldExploration #MbeProject #MiningInCameroon #DrillingCampaign #MartinRosser #GoldInvestment #MiningNews #ResourceExploration #ProactiveUpdates

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF) CEO George Bennett joined Proactive's Stephen Gunnion with details of an interim report on the company's Phalaborwa rare earth project. Bennett detailed the findings of the newly released interim study, emphasising its confirmation of the project’s economic viability despite two years of inflation since the Preliminary Economic Assessment (PEA).

He highlighted that the projected capital expenditure (CapEx) remained below inflation-adjusted expectations due to significant technical optimisations. Operating costs were also reported as highly competitive, with costs for magnet rare earths just above $40 per kilogram. Bennett reiterated the project’s potential to be one of the highest-margin rare earths projects outside China, supported by independent validation from Argus Media.

Bennett also outlined plans to further optimise operational efficiency, including exploring renewable energy options such as solar power. Additionally, the interim study did not include revenue projections from byproducts like gypsum, leaving room for potential upside in the final Definitive Feasibility Study (DFS), expected next year.

He added that the company is preparing its pilot plant in South Africa for separation and purity testing, with results expected in early 2025. Bennett concluded by expressing confidence in the project's robust fundamentals and the team's progress.

Visit Proactive's YouTube channel for more updates, and don’t forget to like, subscribe, and enable notifications to stay informed.

#RareEarths #RainbowRareEarths #MiningUpdates #PhalaborwaProject #GeorgeBennett #MineralResources #SustainableMining #RenewableEnergy #InvestmentOpportunities

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

​​​​​​​Ondo InsurTech PLC (LSE:ONDO) CEO Craig Foster talked with Proactive about the company’s milestones in 2024 and its plans for 2025. Foster highlighted the company's successful US expansion, driven by its LeakBot strategy, which has seen deployments with major insurers, including Nationwide. Revenue grew by 42% in the first half to £1.70 million, signalling the company’s inflection point in the US market.

Foster explained how partnerships have enabled the company to expand rapidly across 16 states, with other insurers like Indiana Farm Bureau joining as partners. He also discussed the NFU deal in the UK and the significant growth in Denmark, doubling the addressable market. Foster assured investors that Ondo's negative working capital model ensures sustainable growth without additional funding requirements.

"We've structured deals so customers finance our growth," Foster said, emphasising a strategic approach to managing working capital and achieving EBITDA-positive trading by the second half of 2025.

With more deals in the pipeline, Foster called 2025 an "exciting year" focused on expanding core markets in Denmark, Sweden, the UK, and the US.

Stay tuned to Proactive's YouTube channel for more insights, and don’t forget to like, subscribe, and enable notifications for future updates.

#OndoInsurTech #CraigFoster #InsurTech #USExpansion #LeakBot #RevenueGrowth #ProactiveInterviews #InsuranceTech #InvestmentNews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Zero Candida Co-Founder and CEO Eli Ben-Haroosh joined Steve Darling from Proactive to share with Proactive that the company has been granted a final patent in South Africa as part of its efforts to establish a global patent portfolio. Applications have also been filed in the United States, Brazil, and Europe.

The company is developing an AI-driven smart tampon-like device that utilizes a therapeutic blue light with precise wavelength and intensity to achieve a 99.999% success rate in treating the Candida fungus overnight at the point of care. This groundbreaking technology targets Vulvo-Vaginal Candidiasis, a condition affecting 75% of women worldwide, and offers a chemical-free treatment without side effects.

Zero Candida’s innovative ZCT device is designed to bridge healthcare gaps, especially in underserved and developing regions. It enables hybrid medical services by collecting and transmitting treatment data to gynecologists in real time via a built-in Wi-Fi chip and VoIP, allowing for remote care, personalized treatment, and ongoing monitoring.

Ben-Haroosh emphasized that the device's combination of effectiveness, side-effect-free treatment, and seamless data integration responds to the growing demand for safer, non-invasive solutions in women’s health. The ZCT device represents a transformative step in accessible, high-tech gynecological care.

#proactiveinvestors #zerocandida #tsxv #zct

#HealthTech #WomensHealth #AIInnovation #CandidaTreatment #NonDrugTherapy #GlobalPatents #MedicalDevices #ProactiveInvestors

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's transformative plans for 2025, emphasizing significant milestones and clinical developments.

Reflecting on 2024, Vitt highlighted progress in the ENSURE-1 and ENSURE-2 Phase 3 studies for relapsing multiple sclerosis (MS), which are on track for completion in 2026. A key achievement of the year was a successful interim analysis, which maintained the study's integrity without adjustments.

On the corporate front, Immunic secured a PIPE investment of up to $240 million, providing a cash runway into Q3 2025 based on the additional $80 million tranche. Vitt said the company also welcomed Jason Tardio as chief operating officer, whose extensive experience in MS commercialization will be pivotal as Immunic prepares for potential product launches.

Looking ahead, April 2025 will bring the clinical readout of the CALLIPER study for progressive MS. Vitt believes vidofludimus calcium has the potential to become the first holistic oral treatment for all forms of MS, a breakthrough based on promising Phase 2 and biomarker data.

Visit Proactive's YouTube channel for more videos. Don’t forget to like, subscribe, and turn on notifications for future updates.

#ImmunicInc #MultipleSclerosis #MSResearch #ClinicalTrials #VidofludimusCalcium #HealthcareInnovation #PIPEInvestment #MedicalBreakthroughs #BiotechNews

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews